Medicare AdvantageCoverageMedium impact
MA08.085i, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
The medical necessity criteria for Rylaze® (asparaginase Erwinia chrysanthemi recombinant-rywn) have been updated for Medicare Advantage plans. This affects billing and coverage determination for this specialized cancer medication used when patients develop allergies to other asparaginase products.
Action Required
Immediately: Review updated medical necessity criteria for Rylaze® (asparaginase Erwinia chrysanthemi recombinant-rywn) in Medicare Advantage plans. Ensure providers document appropriate medical necessity requirements before prescribing. Update prior authorization workflows if additional documentation is now required for coverage approval.